| Page 1239 | Kisaco Research

Privacy- enhancing technologies have been demonstrated as technically effective- but that is not enough. Their implementation requires resource allocation, both in terms of acquiring the technology and subsequently monitoring it.

  • Establishing how PETs can deliver additional business value through unlocking previously inaccessible data
  • Practical first-hand examples successfully identifying relevant use cases, establishing proof of concept and seeing tangible return upon implementation
  • Learning how to quantifiably measure that return over time and assess the need for potential amendments or new areas of application

Author:

Dr. Walden “Wally” Rhines

President & CEO
Cornami

WALDEN C. RHINES is President & CEO of Cornami. He is also CEO Emeritus of Mentor, a Siemens business, focusing on external communications and customer relations. He was previously CEO of Mentor Graphics for 23 years and Chairman of the Board for 17 years. During his tenure at Mentor, revenue nearly quadrupled and market value of the company increased 10X.

Prior to joining Mentor Graphics, Dr. Rhines was Executive Vice President, Semiconductor Group, responsible for TI’s worldwide semiconductor business. During his 21 years at TI, he was President of the Data Systems Group and held numerous other semiconductor executive management positions.

Dr. Rhines has served on the boards of Cirrus Logic, QORVO, TriQuint Semiconductor, Global Logic and as Chairman of the Electronic Design Automation Consortium (five two-year terms) and is currently a director. He is also a board member of the Semiconductor Research Corporation and First Growth Children & Family Charities. He is a Lifetime Fellow of the IEEE and has served on the Board of Trustees of Lewis and Clark College, the National Advisory Board of the University of Michigan and Industrial Committees advising Stanford University and the University of Florida.

Dr. Rhines holds a Bachelor of Science degree in engineering from the University of Michigan, a Master of Science and PhD in materials science and engineering from Stanford University, a master of Business Administration from Southern Methodist University and Honorary Doctor of Technology degrees from the University of Florida and Nottingham Trent University.

Dr. Walden “Wally” Rhines

President & CEO
Cornami

WALDEN C. RHINES is President & CEO of Cornami. He is also CEO Emeritus of Mentor, a Siemens business, focusing on external communications and customer relations. He was previously CEO of Mentor Graphics for 23 years and Chairman of the Board for 17 years. During his tenure at Mentor, revenue nearly quadrupled and market value of the company increased 10X.

Prior to joining Mentor Graphics, Dr. Rhines was Executive Vice President, Semiconductor Group, responsible for TI’s worldwide semiconductor business. During his 21 years at TI, he was President of the Data Systems Group and held numerous other semiconductor executive management positions.

Dr. Rhines has served on the boards of Cirrus Logic, QORVO, TriQuint Semiconductor, Global Logic and as Chairman of the Electronic Design Automation Consortium (five two-year terms) and is currently a director. He is also a board member of the Semiconductor Research Corporation and First Growth Children & Family Charities. He is a Lifetime Fellow of the IEEE and has served on the Board of Trustees of Lewis and Clark College, the National Advisory Board of the University of Michigan and Industrial Committees advising Stanford University and the University of Florida.

Dr. Rhines holds a Bachelor of Science degree in engineering from the University of Michigan, a Master of Science and PhD in materials science and engineering from Stanford University, a master of Business Administration from Southern Methodist University and Honorary Doctor of Technology degrees from the University of Florida and Nottingham Trent University.

Author:

Lawrence Lundy-Bryan

Partner, Research
Lunar Ventures

Lawrence is a deep tech researcher and investor. He is a Partner for Research at Lunar Ventures, a deep tech venture fund where he focuses on horizon scanning. He developed stateofthefuture.xyz, a deep tech tracker, monitoring over 100+ technologies, and writes weekly stateofthefuture.substack.com. He published an investment thesis on privacy-enhancing technologies in 2021. He has previously advised the UK Government, EU Commission, and World Economic Forum on emerging technologies. 

Lawrence Lundy-Bryan

Partner, Research
Lunar Ventures

Lawrence is a deep tech researcher and investor. He is a Partner for Research at Lunar Ventures, a deep tech venture fund where he focuses on horizon scanning. He developed stateofthefuture.xyz, a deep tech tracker, monitoring over 100+ technologies, and writes weekly stateofthefuture.substack.com. He published an investment thesis on privacy-enhancing technologies in 2021. He has previously advised the UK Government, EU Commission, and World Economic Forum on emerging technologies. 

Author:

Robin Smith

Head, Cyber and Information Security
Aston Martin

Robin Smith

Head, Cyber and Information Security
Aston Martin

Author:

Nick New

Founder
Optalysys

Founded Optalysys in 2013 with twenty years experience in Fourier optical processing, having previously spun Cambridge Correlators Ltd. out of the University of Cambridge from technology developed during PhD in Optical Pattern Recognition.

Nick New

Founder
Optalysys

Founded Optalysys in 2013 with twenty years experience in Fourier optical processing, having previously spun Cambridge Correlators Ltd. out of the University of Cambridge from technology developed during PhD in Optical Pattern Recognition.

 

Adrelia Allen

Sr. Director, Clinical Trial Patient Diversity
Merck

Adrelia is a 23-year veteran of the pharmaceutical industry working in sales and clinical research at Merck.  She has held positions of increasing experience as a Clinical Research Associate, Clinical Trial Project Manager, and Clinical Research Manager.  She is currently, the Senior Director of Clinical Trial Patient Diversity where she leads a team of clinical trial operations experts focused on promoting inclusive research practices to support the enrollment of diverse patients in Merck clinical trials.  She is responsible for the execution and strategy implementation for clinical trial

Adrelia Allen

Sr. Director, Clinical Trial Patient Diversity
Merck

Adrelia Allen

Sr. Director, Clinical Trial Patient Diversity
Merck

Adrelia is a 23-year veteran of the pharmaceutical industry working in sales and clinical research at Merck.  She has held positions of increasing experience as a Clinical Research Associate, Clinical Trial Project Manager, and Clinical Research Manager.  She is currently, the Senior Director of Clinical Trial Patient Diversity where she leads a team of clinical trial operations experts focused on promoting inclusive research practices to support the enrollment of diverse patients in Merck clinical trials.  She is responsible for the execution and strategy implementation for clinical trial processes, resources, and training to help drive inclusion and access across our clinical trial portfolio.  Due to her commitment and determination to drive greater representation in clinical trials, Adrelia was recently selected as one of the 100 Most Inspiring People in the life sciences sponsored by PharmaVoice.

Adrelia earned a Doctor of Pharmacy degree from the College of Pharmacy at Florida A&M University.  She is a registered Pharmacist and a certified Project Management Professional. 

 

 

 

Joel Berry

Director of Biology
Felix Biotechnologies

Joel Berry

Director of Biology
Felix Biotechnologies

Joel Berry

Director of Biology
Felix Biotechnologies
 

Stephen Theriault

Chief Executive Officer & Chief Scientific Officer
Cytophage Technologies

Stephen Theriault

Chief Executive Officer & Chief Scientific Officer
Cytophage Technologies

Stephen Theriault

Chief Executive Officer & Chief Scientific Officer
Cytophage Technologies
 

Katherine Donovan

Lead Scientist, Fischer Lab
DFCI

Katherine Donovan is a Lead Scientist in the Fischer Lab where she works on the development of molecular-glues and PROTAC molecules for targeted protein degradation. After joining the Fischer Lab as a Postdoc she developed an interest in proteomics as a specialized technology for quantifying protein-level expression changes in response to various perturbations. Katherine set up and led proteomics teams focused on degrader screening and target identification in the Fischer Lab as well as in the Center for Protein Degradation.

Katherine Donovan

Lead Scientist, Fischer Lab
DFCI

Katherine Donovan

Lead Scientist, Fischer Lab
DFCI

Katherine Donovan is a Lead Scientist in the Fischer Lab where she works on the development of molecular-glues and PROTAC molecules for targeted protein degradation. After joining the Fischer Lab as a Postdoc she developed an interest in proteomics as a specialized technology for quantifying protein-level expression changes in response to various perturbations. Katherine set up and led proteomics teams focused on degrader screening and target identification in the Fischer Lab as well as in the Center for Protein Degradation. She has used proteomics technology to identify the degradation targets of many molecules including the identification of SALL4 as the protein likely underlying the teratogenicity of thalidomide. Katherine led a large effort to map the degradable kinome and now to aid her quest to map the degradable proteome she has recently started a public degradation proteomics initiative which provides free target mapping of degraders.

 

Fia Navntoft

Senior Clinical Project Manager
Molnlycke

Fia Navntoft

Senior Clinical Project Manager
Molnlycke

Fia Navntoft

Senior Clinical Project Manager
Molnlycke
 

Kimberly Doggett

Senior Director, Clinical Trial Diversity
BeiGene

Kimberly Doggett

Senior Director, Clinical Trial Diversity
BeiGene

Kimberly Doggett

Senior Director, Clinical Trial Diversity
BeiGene